Shire Announces FDA Approval Of Once-Daily INTUNIV⢠Extended Release Tablets For The Treatment Of ADHD In Children And Adolescents Aged 6 To 17

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIVâ„¢ (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years.